14 Results for "

Type+I+IFN

" in MedChemExpress (MCE) Product Catalog:
Products (14)

14 Results for "Type+I+IFN" in MCE Product Catalog:

77
77 Publications Verification
Cat. No.: HY-10964
CAS No.: 117570-53-3
Purity:  99.93%
Synonyms: DMXAA; ASA-404
Research Areas:  

Infection Cancer

Vadimezan (DMXAA), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
loading...
    loading...
35
35 Cited Publications
Cat. No.: HY-117287
CAS No.: 1609392-27-9
Purity:  99.87%
Synonyms: BMS-986165
Deucravacitinib (BMS-986165) is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-12326A
CAS No.: 2734909-87-4
Synonyms: Cyclic diadenylate disodium; Cyclic-di-AMP disodium
c-di-AMP (Cyclic diadenylate) sodium is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP sodium is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP sodium acts as a potent mucosal adjuvant stimulating both humoral and cellular responses .
loading...
    loading...
19
19 Cited Publications
Cat. No.: HY-12326B
Purity:  99.36%
Synonyms: Cyclic diadenylate diammonium; Cyclic-di-AMP diammonium
c-di-AMP diammonium is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP diammonium is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP diammonium acts as a potent mucosal adjuvant stimulating both humoral and cellular responses .
loading...
    loading...
Cat. No.: HY-12326
CAS No.: 54447-84-6
Synonyms: Cyclic diadenylate; Cyclic-di-AMP
c-di-AMP (Cyclic diadenylate) is a STING agonist, which binds to the transmembrane protein STING thereby activating the TBK3-IRF3 signaling pathway, subsequently triggering the production of type I IFN and TNF. c-di-AMP (Cyclic diadenylate) is also a bacterial second messenger, which regulates cell growth, survival, and virulence, primarily within Gram-positive bacteria, and also regulates host immune response. c-di-AMP (Cyclic diadenylate) acts as a potent mucosal adjuvant stimulating both humoral and cellular responses .
loading...
    loading...
Cat. No.: HY-125390
CAS No.: 226907-52-4
Purity:  99.41%
Synonyms: CL-087
Research Areas:  

Inflammation/Immunology Cancer

SM-360320 (CL-087) is a potent, orally active TLR7 agonist. SM-360320 is a immuno-modulator and exerts an antitumor effect. SM-360320 can act in synergy with DNA vaccines leading to an enhanced Th1 antibody response . SM-360320 can inhibit HCV replication in hepatocytes via a type I IFN-independent mechanism in addition to its IFN-mediated activity .
loading...
    loading...
Cat. No.: HY-N16021
CAS No.: 2260669-09-6
4A-MPLA ammonium is an orally active TLR4 agonist. 4A-MPLA ammonium induces TLR4 endocytosis dependent on Cdc42 and galectin-3, triggering TRIF-mediated signaling and sustained IFN-β production. 4A-MPLA ammonium promotes lipid droplet formation, upregulates interferon-stimulated genes and type I IFN signaling genes, downregulates lysosome/phagosome function genes, and modulates tolerogenic dendritic cell function. 4A-MPLA ammonium can be used for the research of colitis .
loading...
    loading...
Cat. No.: HY-10964R
CAS No.: 117570-53-3
Synonyms: DMXAA (Standard); ASA-404 (Standard)
Vadimezan (Standard) (DMXAA (Standard)) is the analytical standard of Vadimezan (HY-10964). This product is intended for research and analytical applications. Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan is unable to activate human STING. Vadimezan has anti-influenza virus H1N1-PR8 activities.
loading...
    loading...
Cat. No.: HY-P99478
CAS No.: 163796-60-9

Target:  

IFNAR

Research Areas:  

Inflammation/Immunology

Bifarcept is an interferon receptor type I (IFN-RI) fusion protein. Bifarcept can bind interferon receptors and prolong its serum half-life .
loading...
    loading...
Cat. No.: HY-159857
Synonyms: Gp(2′-5′)Ap(3′) sodium; 2'5'-GpAp sodium; Guanylyl-(2′→5′)-3′-adenylic acid sodium
Gp(2′-5′)Ap sodium is a linear dinucleotide analog after hydrolysis of cyclic guanosine monophosphate- adenosine monophosphate (2’3’-cGAMP) by phosphodiesterases. Due to its linear conformation, 2’5’GpAp is intended to serve as a negative control for 2’3’-cGAMP in type I IFN induction assays.
loading...
    loading...
Cat. No.: HY-117287A
CAS No.: 1609392-28-0
Synonyms: BMS-986165 (hydrochloride)
Research Areas:  

Inflammation/Immunology

Deucravacitinib (BMS-986165) hydrochloride is an orally active allosteric inhibitor of tyrosine kinase 2 (TYK2), with an IC50 of 0.2 nM and a Ki of 0.02 nM against the JH2 domain of TYK2, and it exhibits selectivity over other JAK subtypes and most of the kinome. Deucravacitinib hydrochloride blocks IL-23, IL-12, p-STAT1/3 and Type I IFN signaling, and inhibits Th17/Th1-mediated psoriasis inflammation . Deucravacitinib hydrochloride can be used in research related to moderate-to-severe plaque psoriasis, inflammatory bowel disease and systemic lupus erythematosus .
loading...
    loading...
Cat. No.: HY-184866
CAS No.: 2824164-06-7
Target:  

JAK

Research Areas:  

Inflammation/Immunology

Tyk2-IN-26 (compound 18) is a TYK2 inhibitor that suppresses TYK2/STAT signaling induced by IL-23 and IFNα, with IC50 values all below 30 nM. Tyk2-IN-26 is applicable to research related to TYK2, IL-23, type I IFN signaling, as well as inflammatory immunity .
loading...
    loading...
Cat. No.: HY-182797
CAS No.: 3117340-01-6
Research Areas:  

Cancer

NHWL071065 is a CRBN-targeting IKZF1/IKZF3 molecular glues degrader. NHWL071065 selectively degrades IKZF1 and IKZF3 in lymphoma cells via the ubiquitin-proteasome pathway. NHWL071065 inhibits the proliferation of lymphoma cells. NHWL071065 downregulates proteins involved in cytoskeleton assembly, cell adhesion and immune regulation in cells, while upregulating proteins related to the type I IFN signaling pathway. NHWL071065 can be used in the research of lymphoma .
loading...
    loading...
Cat. No.: HY-166594S
Deucravacitinib- 13C,d3 is the 13C- and deuterium labeled Deucravacitinib. Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis .
loading...
    loading...
  • 1